Novartis Ag ADR (NVS): Congress and insider trades
Who in Congress and inside the company traded NVS, when each filing appeared, and what buying after each one would have earned against the S&P 500.
Key Facts
- Novartis Ag ADR (NVS) is a listed stock on NYSE.
- 11 members of Congress filed 14 buys and 17 sells of NVS, the latest published 2026-07-21 (21 July 2026).
- Across 10 scored buys, Congress averaged -3.0% against the S&P 500 (SPY) over the 90 days after disclosure, with 30% of them ahead of the index. That result is based on too few months of entries (9) to judge.
- Data as of 2026-09-29 (29 September 2026).
Congress trades in NVS
as of 2026-07-21| Filed | Member | Type | Size | Days to file | 90 day vs S&P |
|---|---|---|---|---|---|
| 21 Jul 2026 | Alan Armstrong (R-OK) | buy | 1K–15K | 112 | n/a |
| 21 Jul 2026 | Alan Armstrong (R-OK) | buy | 15K–50K | 113 | n/a |
| 9 Apr 2026 | Ro Khanna (D-CA) | sell | 1K–15K | 25 | n/a |
| 12 Mar 2026 | Ro Khanna (D-CA) | buy | 1K–15K | 24 | -11.4% |
| 12 Mar 2026 | Ro Khanna (D-CA) | sell | 1K–15K | 24 | n/a |
| 17 Oct 2023 | Sheldon Whitehouse (D-RI) | buy | 15K–50K | 27 | +1.2% |
| 14 Aug 2023 | Daniel S. Goldman (D-NY) | sell | 50K–100K | 34 | n/a |
| 14 Jun 2023 | Ro Khanna (D-CA) | buy | 1K–15K | 31 | -1.9% |
| 10 May 2023 | Ro Khanna (D-CA) | buy | 1K–15K | 24 | -8.6% |
| 1 May 2023 | Tom Carper (D-DE) | buy | 1K–15K | 5 | -10.5% |
| 17 Apr 2023 | Daniel S. Goldman (D-NY) | buy | 50K–100K | 17 | -7.6% |
| 21 Mar 2023 | Daniel S. Goldman (D-NY) | sell | 15K–50K | 21 | n/a |
| 10 Mar 2023 | Ro Khanna (D-CA) | buy | 15K–50K | 26 | +11.7% |
| 15 Feb 2023 | Kevin Hern (R-OK) | sell | 1K–15K | 14 | n/a |
| 20 Apr 2022 | John Rutherford (R-FL) | sell | 1K–15K | 34 | n/a |
| 4 Mar 2022 | Don Beyer (D-VA) | sell | 1K–15K | 3 | n/a |
| 9 Feb 2022 | Ro Khanna (D-CA) | sell | 15K–50K | 18 | n/a |
| 1 Feb 2022 | Don Beyer (D-VA) | buy | 1K–15K | 5 | +14.8% |
| 21 Jan 2022 | Shelley Moore Capito (R-WV) | sell | 1K–15K | 37 | n/a |
| 3 Jan 2022 | Don Beyer (D-VA) | sell | 1K–15K | 10 | n/a |
| 2 Oct 2021 | Don Beyer (D-VA) | sell | 1K–15K | 14 | n/a |
| 16 Sep 2021 | Ro Khanna (D-CA) | buy | 15K–50K | 15 | -2.6% |
| 16 Jan 2021 | Phil Roe (R-TN) | sell | 1K–15K | 24 | n/a |
| 16 Jan 2021 | Phil Roe (R-TN) | buy | 1K–15K | 15 | -14.9% |
| 12 Dec 2020 | Phil Roe (R-TN) | buy | 1K–15K | 32 | n/a |
| 4 Dec 2020 | Alan Lowenthal (D-CA) | sell | 15K–50K | 10 | n/a |
| 4 Dec 2020 | Alan Lowenthal (D-CA) | sell | 1K–15K | 10 | n/a |
| 2 Dec 2020 | Don Beyer (D-VA) | buy | 1K–15K | 14 | n/a |
| 17 Nov 2020 | Phil Roe (R-TN) | sell | 1K–15K | 42 | n/a |
| 17 Nov 2020 | Phil Roe (R-TN) | sell | 1K–15K | 41 | n/a |
| 6 Nov 2020 | Don Beyer (D-VA) | sell | 1K–15K | 31 | n/a |
Nothing matches that search.
Related pages
Frequently asked questions
Who has bought NVS?
14 Congress buys by 11 members and 0 insider buys are on file. The tables on this page list every one.
Did buying NVS after a disclosure beat the market?
Across 10 scored buys, Congress averaged -3.0% against the S&P 500 (SPY) over the 90 days after disclosure, with 30% of them ahead of the index. That result is based on too few months of entries (9) to judge. A single stock is a small sample.
Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.
Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.